

ASTRAZENECA PLC  
Form 6-K  
March 08, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2017

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes \_\_\_ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

8 March 2017 07:00 GMT

**FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION**

AstraZeneca PLC (the Company) announced today that, on 7 March 2017, it filed its 2016 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at [www.sec.gov](http://www.sec.gov) and also on the Company's website at [www.astrazeneca.com](http://www.astrazeneca.com). The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

**Media Enquiries**

|                     |                            |                  |
|---------------------|----------------------------|------------------|
| Esra Erkal-Paler    | UK/Global                  | +44 203 749 5638 |
| Vanessa Rhodes      | UK/Global                  | +44 203 749 5736 |
| Karen Birmingham    | UK/Global                  | +44 203 749 5634 |
| Rob Skelding        | UK/Global                  | +44 203 749 5821 |
| Jacob Lund          | Sweden                     | +46 8 553 260 20 |
| Michele Meixell     | US                         | +1 302 885 2677  |
| Investor Relations  |                            |                  |
| Thomas Kudsk Larsen |                            | +44 203 749 5712 |
| Craig Marks         | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Henry Wheeler       | Oncology                   | +44 203 749 5797 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                                  |                                        |                                     |
|----------------------------------|----------------------------------------|-------------------------------------|
| Mitchell Chan                    | Oncology                               | +1 240 477 3771                     |
| Lindsey Trickett                 | Cardiovascular & Metabolic Diseases    | +1 240 543 7970                     |
| Nick Stone                       | Respiratory                            | +44 203 749 5716                    |
| Christer Gruvris<br>US toll free | Autoimmunity, Neuroscience & Infection | +44 203 749 5711<br>+1 866 381 7277 |

Adrian Kemp  
Company Secretary, AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 08 March 2017 By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary